BRPI1008566A2 - métodos e composições para o diagnóstico e tratamento de câncer - Google Patents

métodos e composições para o diagnóstico e tratamento de câncer

Info

Publication number
BRPI1008566A2
BRPI1008566A2 BRPI1008566A BRPI1008566A BRPI1008566A2 BR PI1008566 A2 BRPI1008566 A2 BR PI1008566A2 BR PI1008566 A BRPI1008566 A BR PI1008566A BR PI1008566 A BRPI1008566 A BR PI1008566A BR PI1008566 A2 BRPI1008566 A2 BR PI1008566A2
Authority
BR
Brazil
Prior art keywords
compositions
treatment
methods
cancer diagnosis
diagnosis
Prior art date
Application number
BRPI1008566A
Other languages
English (en)
Inventor
Koslowski Michael
Sahin Ugur
Türeci Özlem
Original Assignee
Ganymed Pharmaceuticas Ag
Johannes Gutenberg-Universität Mainz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticas Ag, Johannes Gutenberg-Universität Mainz filed Critical Ganymed Pharmaceuticas Ag
Publication of BRPI1008566A2 publication Critical patent/BRPI1008566A2/pt
Publication of BRPI1008566A8 publication Critical patent/BRPI1008566A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1008566A 2009-02-20 2010-02-18 métodos e composições para o diagnóstico e tratamento de câncer BRPI1008566A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15415909P 2009-02-20 2009-02-20
EP09002458A EP2221063A1 (en) 2009-02-20 2009-02-20 Methods and compositions for diagnosis and treatment of cancer
PCT/EP2010/001035 WO2010094490A1 (en) 2009-02-20 2010-02-18 Methods and compositions for diagnosis and treatment of cancer

Publications (2)

Publication Number Publication Date
BRPI1008566A2 true BRPI1008566A2 (pt) 2017-06-06
BRPI1008566A8 BRPI1008566A8 (pt) 2018-01-02

Family

ID=40594202

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008566A BRPI1008566A8 (pt) 2009-02-20 2010-02-18 métodos e composições para o diagnóstico e tratamento de câncer

Country Status (14)

Country Link
US (1) US9637548B2 (pt)
EP (3) EP2221063A1 (pt)
JP (2) JP5809067B2 (pt)
KR (1) KR20110128315A (pt)
CN (1) CN102325548A (pt)
AU (1) AU2010215691B2 (pt)
BR (1) BRPI1008566A8 (pt)
CA (1) CA2750980A1 (pt)
IL (1) IL214255B (pt)
MX (2) MX349996B (pt)
NZ (2) NZ594479A (pt)
SG (2) SG173033A1 (pt)
WO (1) WO2010094490A1 (pt)
ZA (1) ZA201105472B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
MX2011008430A (es) 2009-02-20 2011-09-29 Ganymed Pharmaceuticals Ag Metodos y composiciones para diagnostico y tratamiento del cancer.
AU2015255252B2 (en) * 2009-02-20 2017-11-23 BioNTech SE Methods and compositions for diagnosis and treatment of cancer
EP3689911B1 (en) 2009-11-11 2024-08-21 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3026064B1 (en) 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
US9717781B2 (en) * 2011-08-08 2017-08-01 Alexander Shneider Methods and compositions relating to P62 for the treatment and prophylaxis of cancer
WO2013023059A2 (en) 2011-08-10 2013-02-14 Lankenau Institute For Medical Research Methods and compositions for the treatment of autoimmune and inflammatory diseases
US20150166630A1 (en) * 2012-07-19 2015-06-18 Amgen Inc. Btnl3 proteins, nucleic acids, and antibodies and uses thereof
KR101329655B1 (ko) * 2012-12-13 2013-11-14 강원대학교산학협력단 수압식 안마장치 및 그의 제어방법
JP2016512197A (ja) * 2013-03-05 2016-04-25 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 間葉及び上皮間葉形質転換循環腫瘍細胞のための特異的検出ツール
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
CN104634907B (zh) * 2013-11-11 2018-04-20 上海交通大学医学院附属瑞金医院 一类氨基酸分子组合作为胃癌标志物的用途
JP2021512875A (ja) * 2018-02-02 2021-05-20 カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． 細胞免疫療法の組み合わせ
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
WO2022048314A1 (zh) * 2020-09-03 2022-03-10 上海易慕峰生物科技有限公司 针对循环肿瘤细胞的免疫杀伤细胞在实体瘤治疗中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) * 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20030166132A1 (en) * 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2002536995A (ja) 1999-02-22 2002-11-05 インサイト・ファーマスーティカルズ・インコーポレイテッド 結腸の疾患に関連する遺伝子
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
EP1409549A4 (en) * 2001-06-20 2007-10-24 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
US20080305493A1 (en) 2004-03-08 2008-12-11 Avalon Pharmaceuticals Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CA2721072A1 (en) 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
MX2011008430A (es) * 2009-02-20 2011-09-29 Ganymed Pharmaceuticals Ag Metodos y composiciones para diagnostico y tratamiento del cancer.
US20150166630A1 (en) 2012-07-19 2015-06-18 Amgen Inc. Btnl3 proteins, nucleic acids, and antibodies and uses thereof

Also Published As

Publication number Publication date
EP2221063A1 (en) 2010-08-25
US9637548B2 (en) 2017-05-02
BRPI1008566A8 (pt) 2018-01-02
NZ601793A (en) 2013-11-29
IL214255B (en) 2018-05-31
WO2010094490A1 (en) 2010-08-26
KR20110128315A (ko) 2011-11-29
JP5809067B2 (ja) 2015-11-10
EP2398497A1 (en) 2011-12-28
JP2012518608A (ja) 2012-08-16
ZA201105472B (en) 2012-10-31
CA2750980A1 (en) 2010-08-26
SG10201402491YA (en) 2014-07-30
AU2010215691B2 (en) 2015-09-03
NZ594479A (en) 2013-06-28
JP2016040253A (ja) 2016-03-24
EP3170511A1 (en) 2017-05-24
SG173033A1 (en) 2011-08-29
MX2011008429A (es) 2011-09-29
IL214255A0 (en) 2011-09-27
AU2010215691A1 (en) 2011-08-18
CN102325548A (zh) 2012-01-18
US20110318264A1 (en) 2011-12-29
MX349996B (es) 2017-08-23

Similar Documents

Publication Publication Date Title
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
PT2340042E (pt) Métodos e composições para o tratamento de cancro
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
BR112012005594A2 (pt) tratamento de câncer
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
IL258794B (en) Methods and compositions for diagnosis and treatment of cancer
PT2632452T (pt) Compostos e composições para o tratamento do cancro
BRPI1010874A2 (pt) composição para o tratamento de câncer de próstata
PT2512502T (pt) Métodos e composições para supressão de tumores
BRPI0911112A2 (pt) composições e métodos para o tratamento do câncer de mama
BRPI1009920A2 (pt) composições bacterianas para profilaxina e tratamento de doença degenerativa.
SG10201402491YA (en) Methods and compositions for diagnosis and treatment of cancer
BRPI1007600A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0922884A2 (pt) compostos para tratamento de câncer
IL240560A0 (en) Compositions and methods for the diagnosis and treatment of tumor
BR112013011659A2 (pt) métodos de tratamento do câncer
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2501 DE 11-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.